Distinct regulatory effect of the p34SEI-1 oncoprotein on cancer metastasis in HER2/neu-positive and -negative cells

By Jung Samil   Ohk Jiyeon   Jeong Dongjun   Li Chengping   Lee Soonduck   Duan Jingjing   Kim Changjin   Lim Jong-Seok   Yang Young   Kim Keun-Il   Lee Myeong-Sok  

International Journal of Oncology, Vol. 45, Iss. 1, 2014-07 ,pp. : 189-196

Spandidos Publications

Access to resources Recommend Favorite

Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast Cancer

By Pusztai Lajos   Esteva Francisco  

Cancer Investigation, Vol. 24, Iss. 2, 2006-05 ,pp. : 187-191

Informa Healthcare

Access to resources Recommend Favorite

Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2- neu -positive breast cancer? A current debate

By Petrelli Fausto  

Medical Oncology, Vol. 28, Iss. 2, 2011-06 ,pp. : 401-408

Humana Press, Inc

Access to resources Recommend Favorite

Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US

By Cronin Kathleen A.   Harlan Linda C.   Dodd Kevin W.   Abrams Jeffrey S.   Ballard-Barbash Rachel  

Cancer Investigation, Vol. 28, Iss. 9, 2010-10 ,pp. : 963-968

Informa Healthcare

Access to resources Recommend Favorite

Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer

By Hayashi Naoki  

International Journal of Clinical Oncology, Vol. 17, Iss. 2, 2012-04 ,pp. : 96-104

Springer Publishing Company

Access to resources Recommend Favorite